Humedics Joint Injection 'Humiaju' Obtains European CE Certification

Humedics CI (Photo by Humedics)

[Asia Economy Reporter Chunhee Lee] Humedix announced on the 27th that its single-dose osteoarthritis treatment 'HUMIA' recently obtained the European CE certification.

HUMIA's efficacy lasts for six months with a single administration. It combines Humedix's proprietary bio-polymer application biotechnology with high-purity hyaluronic acid production technology, resulting in a structure similar to the synovial fluid properties of normal joints.

Previously, in 2019, it received product approval from the Ministry of Food and Drug Safety and has been steadily sold under names such as 'Highhyal One.' CE certification is a regulation set by the European Union (EU) regarding quality, performance, durability, and safety, and can only be obtained when all requirements are met. Acquiring it is essential for targeting the European market.

Humedix plans to accelerate its global market expansion of HUMIA following this CE certification. Unlike existing osteoarthritis treatments with the same formulation that require weekly administration 3 or 5 times, HUMIA significantly reduces the number of doses with a single administration, alleviating patient inconvenience and emphasizing its suitability for the COVID-19 non-face-to-face era.

Jinhwan Kim, CEO of Humedix, stated, “HUMIA is a product developed by integrating Humedix's bio-polymer application biotechnology. We will focus on overseas market expansion to establish it as a leading product in the global hyaluronic acid osteoarthritis treatment market, estimated to be worth approximately 25 trillion KRW.”

This content was produced with the assistance of AI translation services.